Following the discovery that a subset of patients with metastatic urothelial cancer respond to cisplatin-based multidrug chemotherapy, clinicians and patients were faced with the challenge of suboptimal therapeutic options for those patients deemed unfit to receive cisplatin. One consensus definition of cisplatin ineligibility is inadequate renal function (creatinine clearance <60 mL/min), poor Eastern Cooperative Oncology Group (ECOG) performance status (ie, ECOG performance status 2 or greater), or pre-existing peripheral neuropathy or hearing loss.

中文翻译：

---

不适合顺铂治疗的尿路上皮癌的新选择

在发现一部分转移性尿路上皮癌患者对基于顺铂的多药化疗有反应后，对于那些认为不适合接受顺铂的患者，临床医生和患者面临着次优治疗方案的挑战。顺铂不合格的一种共识定义是肾功能不全（肌酐清除率<60 mL / min），东部合作肿瘤小组（ECOG）表现不佳（即ECOG表现为2或更高）或周围神经病变或听力丧失。